Sort
15,273 grants matching “antimicrobial resistance”
A Genomics Based Investigation of the Determinants of Polymicrobial Infectious Disease Outcomes
$3,548,646David A Rasko · University Of Maryland Baltimore · U19 · FY2021 · AI
GH16-006: Conducting Communicable Disease Research in Kenya
$3,539,782M Kariuki Njenga · Washington State University · U01 · FY2020 · GH
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria
$3,511,044Urs Ochsner · Crestone, Inc. · N01 · FY2023 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$3,457,326Jerrold J. Ellner · Rbhs-New Jersey Medical School · U19 · FY2020 · AI
Development of Therapeutics for Antimicrobial Resistant Pathogens
$3,440,594Timothy Henkel · Venatorx Pharmaceuticals, Inc. · N01 · FY2023 · AI
Novel Therapeutics for Bacillus anthracis
$3,440,534Michael E. Johnson · University Of Illinois At Chicago · U19 · FY2007 · AI
Novel Therapeutics for Bacillus anthracis
$3,440,090Michael E. Johnson · University Of Illinois At Chicago · U19 · FY2006 · AI
Advanced Development of Medical Countermeasures for Infectious Diseases
$3,439,774Urs Ochsner · Crestone, Inc. · N01 · FY2019 · AI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities
$3,433,302David R Andes · University Of Wisconsin-Madison · U19 · FY2014 · AI
A Genomics Based Investigation of the Determinants of Polymicrobial Infectious Disease Outcomes
$3,428,670David A Rasko · University Of Maryland Baltimore · U19 · FY2022 · AI
Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
$3,424,537Brian Kane · Spero Therapeutics, Inc. · N01 · FY2024 · AI
Novel Therapeutics for Bacillus anthracis
$3,420,271University Of Illinois At Chicago · U19 · FY2005 · AI
Infectious Diseases Fellowship Program
$3,418,984Christa Zerbe · National Institute Of Allergy And Infectious Diseases · ZIE · FY2022 · AI
A Genomics Based Investigation of the Determinants of Polymicrobial Infectious Disease Outcomes
$3,375,081David A Rasko · University Of Maryland Baltimore · U19 · FY2023 · AI
HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)
$3,372,423Stephen A Spector · University Of California, San Diego · UM1 · FY2019 · AI
PItt-Ohio State-Georgetown Clinical Trials Unit
$3,366,355John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2019 · AI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities
$3,329,683David R Andes · University Of Wisconsin-Madison · U19 · FY2015 · AI
Novel Therapeutics for Bacillus anthracis
$3,320,641University Of Illinois At Chicago · U19 · FY2004 · AI
Development of Therapeutic Candidates for Antibiotic Resistant Bacteria
$3,318,955Paul Joon Kim · Locus Biosciences, Inc. · N01 · FY2025 · AI
Task D01: Pre-Clinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services
$3,314,726Leanne Chan · Sri International · N01 · FY2018 · AI
Sexually Transmitted Infections Clinical Trial Group: Clinical Study of Point-of-Care Diagnostics
$3,309,642Jeffrey Klausner · Social And Scientific Systems, Inc. · N01 · FY2017 · AI
METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS
$3,246,637Katerina Heran Darwin · New York University School Of Medicine · R01 · FY2025 · AI
HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)
$3,241,549Stephen A Spector · University Of California, San Diego · UM1 · FY2020 · AI
MIDAS Center for Communicable Disease Dynamics
$3,231,697Marc Lipsitch · Harvard School Of Public Health · U54 · FY2009 · GM
DEVELOPMENT OF NOVEL COUNTERMEASURES FOR RESPIRATORY DISEASES
$3,227,357Anne Kathleen Radcliff · Cubrc, Inc. · N01 · FY2013 · AI